Vimal Mehta - 01 Aug 2025 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
CEO and President, Director
Signature
/s/ Richard Steinhart, Attorney-in-Fact for Vimal Mehta, Ph.D
Issuer symbol
BTAI
Transactions as of
01 Aug 2025
Net transactions value
$0
Form type
4
Filing time
05 Aug 2025, 20:00:14 UTC
Previous filing
22 Jul 2025
Next filing
16 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mehta Vimal CEO and President, Director C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, 12TH FLOOR, NEW HAVEN /s/ Richard Steinhart, Attorney-in-Fact for Vimal Mehta, Ph.D 05 Aug 2025 0001733369

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Restricted Stock Units Award $0 +18,000 $0.000000 18,000 01 Aug 2025 Common Stock 18,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 18,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date.